---

---

sector : Health technology    tags : Liver   

save search

---

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Published: 2024-04-25 (Crawled : 12:00) - biospace.com/
CANF | $1.94 4.1K |

Health Technology

| Email alert Add to watchlist
liver namodenoson advanced response journal publication

---

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Published: 2024-04-25 (Crawled : 12:00) - biospace.com/
CGEN | $1.91 72K |

Health Technology

| Email alert Add to watchlist
com701 liver asco cancer

---

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
SGMT | News | $4.0 -4.08% 35K |

Health Technology

| 5.04% | O: 5.29% H: 0.0% C: -3.59%
day liver fibrosis

---

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.94 4.1K |

Health Technology

| -7.62% | O: 4.76% H: 0.45% C: -5.91%
drug candidate liver cancer treat namodenoson advanced

---

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.0 14K |

Health Technology

| -1.0% | O: 64.34% H: 4.82% C: -18.67%
fxr314 metabolic liver positive for results

---

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $194.1 -5.16% 88K |

Health Technology

| -16.88% | O: 2.12% H: 0.7% C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash

---

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.361 -9.75% 13K |

Health Technology

| 14.61% | O: 17.48% H: 0.0% C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash

---

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $194.1 -5.16% 88K |

Health Technology

| -15.98% | O: 20.66% H: 2.07% C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced

---

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.94 4.1K |

Health Technology

| -12.22% | O: -0.45% H: 2.27% C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson

---

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $194.1 -5.16% 88K |

Health Technology

| -17.0% | O: -0.86% H: 2.04% C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application

---

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| Email alert Add to watchlist
pharma liver disease fibrosis trial results

---

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
NNOX | News | $8.88 -2.31% 83K |

Health Technology

| 36.9% | O: -6.78% H: 2.42% C: -3.55%
fda liver software clearance advanced

---

Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.47 400K |

Manufacturing

| -12.48% | O: 0.37% H: 0.74% C: 0.28%
BMY | $45.36 -7.16% 10M |

Health Technology

| -1.79% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $166.41 -0.83% 860K |

Health Technology

| -3.05% | O: 0.8% H: 0.0% C: 0.0%
SNY | News | $49.085 5.31% 1.2M |

Health Technology

| 2.69% | O: -0.06% H: 0.0% C: 0.0%
GILD | $65.93 -1.71% 1.9M |

Health Technology

| -9.9% | O: 0.32% H: 0.11% C: -1.55%
ALNY | $142.22 -1.1% 25K |

Health Technology

| -15.08% | O: -2.63% H: 0.98% C: -1.75%
liver disease therapeutics market

---

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $65.93 -1.71% 1.9M |

Health Technology

| -8.95% | O: -0.35% H: 2.36% C: 1.42%
CBAY | $32.48 0.03% 8.4M |

Health Technology

| 30.09% | O: 27.92% H: 0.97% C: 0.88%
liver acquisition sciences therapeutics

---

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $11.28 -5.21% 44K |

Health Technology

| -31.61% | O: -3.62% H: 0.0% C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics

---

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $724.615 -1.04% 480K |

Health Technology

| 19.23% | O: -0.51% H: 0.37% C: 0.32%
MDGL | $194.1 -5.16% 88K |

Health Technology

| -12.24% | O: 1.29% H: 0.35% C: -3.04%
HEPA | $1.32 5.2K |

Health Technology

| -36.84% | O: -0.48% H: 7.69% C: 1.44%
ALT | $7.23 2.12% 570K |

Commercial Services

| -29.48% | O: -0.8% H: 6.02% C: 0.6%
ALNY | $142.22 -1.1% 25K |

Health Technology

| -21.81% | O: 0.46% H: 3.04% C: 2.67%
ETNB | $8.08 -5.83% 88K |

Health Technology

| -21.43% | O: 1.19% H: 0.63% C: -0.72%
liver disease companies key growth market

---

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
Published: 2023-12-07 (Crawled : 06:00) - globenewswire.com
GNFT | $3.49 8 |

Health Technology

| 9.06% | O: 7.19% H: 0.0% C: -6.71%
fda rare drug liver review treatment application grants

---

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
Published: 2023-11-16 (Crawled : 21:00) - globenewswire.com
GNFT | $3.49 8 |

Health Technology

| 7.06% | O: 1.23% H: 1.21% C: -1.21%
meeting liver

---

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 23:00) - prnewswire.com
VIR | $7.665 -4.66% 140K |

Health Technology

| -12.42% | O: 3.92% H: 4.3% C: 3.35%
VBIV | $0.5753 -2.49% 39K |

Health Technology

| -10.47% | O: -2.12% H: 3.78% C: 0.78%
meeting cure liver

---

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PLRX | $11.28 -5.21% 44K |

Health Technology

| -7.39% | O: 4.05% H: 0.6% C: -1.5%
meeting liver therapeutics

---

Gainers vs Losers

46%

54%

Top 10 Gainers

SGBX | $0.26 80.43% 54M |

Producer Manufacturing

LICN | $1.0 78.57% 3.3M |

CSSE 4 | $0.2656 74.39% 9.7M |

Consumer Services

BRFH 4 | $1.89 71.82% 32M |

Manufacturing

ACON | $0.49 70.14% 24M |

n/a

BOF | $1.95 66.67% 920K |

MTC | $3.62 61.61% 790K |

Technology Services

AMST | $3.22 61.0% 720K |

Technology Services

PCSA | $2.28 40.74% 37M |

Producer Manufacturing

EVA | $0.626 39.14% 2.3M |

Process Industries

---

Your saved searches

---